Company Filing History:
Years Active: 2023
Title: Innovations of Eryin Wang in Colorectal Cancer Research
Introduction
Eryin Wang is a notable inventor based in Wuxi, China. He has made significant contributions to the field of microbiology, particularly in the area of colorectal cancer inhibition. His innovative work focuses on developing microbial strains that can effectively combat the onset of colorectal cancer.
Latest Patents
Eryin Wang holds a patent related to a strain known as CCFM164, which has a deposit number CGMCC No. 14520. This strain demonstrates a remarkable ability to inhibit the occurrence of colorectal cancer. It shows good tolerance to gastric acid and bile salts, significantly alleviating colorectal inflammation in model mice. The strain can reduce tumor numbers in the colon and rectum by regulating the Notch1 and Notch2 signaling pathways, as well as the expression of the VEGFR2 molecule in colorectal tissue. Additionally, CCFM164 improves the intestinal flora population and increases short-chain fatty acid levels in the intestine. This strain is utilized to prepare fermented food aimed at preventing colorectal cancer.
Career Highlights
Eryin Wang is affiliated with Jiangnan University, where he continues to advance his research in microbial applications for health benefits. His work has garnered attention for its potential impact on cancer prevention and treatment.
Collaborations
Eryin Wang collaborates with several colleagues, including Gang Wang, who share his commitment to advancing research in microbiology and cancer inhibition.
Conclusion
Eryin Wang's innovative research and patent on the CCFM164 strain highlight his dedication to combating colorectal cancer through microbial technology. His contributions are paving the way for new approaches in cancer prevention and treatment.